Avid Bioservices (CDMO) 10-K2009 FY Annual report

Filed: 14 Jul 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Accelerated, AMI, anniversary, ASCO, AU, bear, bevacizumab, biomanufacturing, BlueCrest, borrow, Canada, certainty, chlorotoxin, clause, Clive, clone, component, conflict, contact, contractor, covenant, credible, customary, DCAA, debar, decision, discretionary, dismissed, division, Eisai, employment, exceeding, FAS, flexibility, floor, FSP, Fussey, halfway, hearing, Hedging, hierarchy, Hu, induced, inibitor, instrument, intercreditor, invoked, JohnsonCarlton, Joseph, kinase, KingSteven, lender, LIBOR, lien, lieu, loan, LytlePaul, MidCap, mix, murine, noncompliant, nongovernmental, Nuclear, objectionable, occasion, organizational, Panel, passage, Peisheng, PohlDavid, possession, PRC, preclinical, prejudice, preserve, proportionately, protest, provisional, ratio, ready, reliance, relieve, relinquished, repay, repayment, segregated, Shan, Shelley, short, shortage, Simon, slight, Smith, Society, solo, spinner, stay, stayed, subcontract, subordinate, subordinated, subordination, succeeding, surpassed, SwartzEric, Taylor, thereof, thousand, tranche, TransMolecular, tyrosine, unbilled, uncured, unexpectedly, unfair, Unfavorable, Unobservable, VEGFR, viewed, Vivatuxin, Wm, worsen

Removed: academic, accessible, analog, Anderson, animal, biodefense, characterized, circumstance, classify, Coagulation, commitment, consortium, Debenture, distributed, Enhancement, enhancing, Estate, estimating, forma, growing, humanization, humanized, Ia, Immunotherapeutic, inconsequential, incremental, involvement, Kendrick, lab, leaseback, lethal, licensee, Maker, Medarex, MGI, Michael, microenvironment, NABTT, negotiating, Northwestern, Oncolym, pancreatic, parent, Payee, payoff, PEP, permeability, Pharma, Pledge, portfolio, principally, private, pro, prodrug, prostate, pursuing, rata, Real, recovery, reserve, retained, sensitive, shipping, Southern, sublease, Subscription, summarize, supplemental, taribavirin, Tenant, TNCA, top, Triton, unusable, uptake, Valeant, Vasculature, Vertical, Viramidine, Waltz, West, wide, ZLP

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CDMO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATIONS OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven W. King, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Peregrine Pharmaceuticals, Inc. on Form 10-K for the year ended April 30, 2009 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Peregrine Pharmaceuticals, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Peregrine Pharmaceuticals, Inc.

	By:	/s/ STEVEN W. KING
	Name:	Steven W. King
	Title:	President & Chief Executive Officer, and Director
	Date:	July 10, 2009

I, Paul J. Lytle, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Peregrine Pharmaceuticals, Inc. on Form 10-K for the year ended April 30, 2009 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report of Peregrine Pharmaceuticals, Inc. on Form 10-K fairly presents in all material respects the financial condition and results of operations of Peregrine Pharmaceuticals, Inc.

	By:	/s/ PAUL J. LYTLE
	Name:	Paul J. Lytle
	Title:	Chief Financial Officer
	Date:	July 10, 2009

A signed original of this written statement required by Section 906 has been provided to Peregrine Pharmaceuticals, Inc. and will be retained by Peregrine Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification is being furnished pursuant to Rule 15(d) and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. This Certification shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.